Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen total Depreciation and Amortization (Cash Flow Statement) ($M) ($M)
Form 10-Q / 10-K Consolidated Statements of Cash Flows (XBRL)
Latest, Q2 2026
1,112
Period ended Jun 30, 2026
Change on a year earlier
-17.1%
1,341 in Q2 2025
History
46 quarters
Since Q1 2015
Sources
36
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Depreciation and Amortization (Cash Flow Statement) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 1,112 | -17.1% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 1,116 | -19.5% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2025 | Dec 31, 2025 | 1,132 | -19.0% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2025 | Sep 30, 2025 | 1,307 | -6.4% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 1,341 | -4.2% | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 1,387 | -0.9% | Form 10-Q (filed 2026-05-01) ↗ |
| Q4 2024 | Dec 31, 2024 | 1,397 | +1.2% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2024 | Sep 30, 2024 | 1,396 | +56.0% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2024 | Jun 30, 2024 | 1,400 | +56.3% | Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2024 | Mar 31, 2024 | 1,399 | +55.4% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,380 | +51.5% | Form 10-K (filed 2026-02-13) ↗ |
| Q3 2023 | Sep 30, 2023 | 895 | +6.9% | Form 10-Q (filed 2024-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 896 | +8.2% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 900 | +7.0% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 911 | +6.9% | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 837 | -1.5% | Form 10-Q (filed 2023-10-31) ↗ |
| Q2 2022 | Jun 30, 2022 | 828 | -3.2% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 841 | 0.0% | Form 10-Q (filed 2023-04-28) ↗ |
| Q4 2021 | Dec 31, 2021 | 852 | -2.4% | Form 10-K (filed 2024-02-14) ↗ |
| Q3 2021 | Sep 30, 2021 | 850 | -5.7% | Form 10-Q (filed 2022-11-04) ↗ |
| Q2 2021 | Jun 30, 2021 | 855 | -8.1% | Form 10-Q (filed 2022-08-05) ↗ |
| Q1 2021 | Mar 31, 2021 | 841 | -6.2% | Form 10-Q (filed 2022-04-28) ↗ |
| Q4 2020 | Dec 31, 2020 | 873 | +24.4% | Form 10-K (filed 2023-02-09) ↗ |
| Q3 2020 | Sep 30, 2020 | 901 | +77.4% | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 930 | +85.6% | Form 10-Q (filed 2021-08-04) ↗ |
| Q1 2020 | Mar 31, 2020 | 897 | +81.2% | Form 10-Q (filed 2021-04-28) ↗ |
| Q4 2019 | Dec 31, 2019 | 702 | +43.3% | Form 10-K (filed 2022-02-16) ↗ |
| Q3 2019 | Sep 30, 2019 | 508 | +1.4% | Form 10-Q (filed 2020-10-29) ↗ |
| Q2 2019 | Jun 30, 2019 | 501 | +3.5% | Form 10-Q (filed 2020-07-29) ↗ |
| Q1 2019 | Mar 31, 2019 | 495 | +5.1% | Form 10-Q (filed 2020-05-01) ↗ |
| Q4 2018 | Dec 31, 2018 | 490 | +9.1% | Form 10-K (filed 2021-02-09) ↗ |
| Q3 2018 | Sep 30, 2018 | 501 | +8.0% | Form 10-Q (filed 2019-10-30) ↗ |
| Q2 2018 | Jun 30, 2018 | 484 | -6.6% | Form 10-Q (filed 2019-07-31) ↗ |
| Q1 2018 | Mar 31, 2018 | 471 | -10.1% | Form 10-Q (filed 2019-05-01) ↗ |
| Q4 2017 | Dec 31, 2017 | 449 | -19.7% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2017 | Sep 30, 2017 | 464 | -7.8% | Form 10-Q (filed 2018-10-31) ↗ |
| Q2 2017 | Jun 30, 2017 | 518 | -0.8% | Form 10-Q (filed 2018-07-27) ↗ |
| Q1 2017 | Mar 31, 2017 | 524 | +0.6% | Form 10-Q (filed 2018-04-25) ↗ |
| Q4 2016 | Dec 31, 2016 | 559 | +3.1% | Form 10-K (filed 2019-02-13) ↗ |
| Q3 2016 | Sep 30, 2016 | 503 | -3.8% | 10-Q FY2016 (XBRL) ↗ |
| Q2 2016 | Jun 30, 2016 | 522 | +0.6% | 10-Q FY2016 (XBRL) ↗ |
| Q1 2016 | Mar 31, 2016 | 521 | -0.6% | 10-Q FY2016 (XBRL) ↗ |
| Q4 2015 | Dec 31, 2015 | 542 | – | Form 10-K (filed 2018-02-13) ↗ |
| Q3 2015 | Sep 30, 2015 | 523 | – | 10-Q FY2015 (XBRL) ↗ |
| Q2 2015 | Jun 30, 2015 | 519 | – | 10-Q FY2015 (XBRL) ↗ |
| Q1 2015 | Mar 31, 2015 | 524 | – | 10-Q FY2015 (XBRL) ↗ |
Cite this data
StockData. (2026). Amgen Total Depreciation and Amortization (Cash Flow Statement) ($M) ($M), quarterly Q1 2015–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/da_cf_tot
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.